Cargando…

Tu1547: COVID-19 VACCINE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS

Detalles Bibliográficos
Autores principales:	Meybodi, Mohamad Aghaie, Rotundo, Laura, Shakoor, Delaram, Brackett, Alexandria, Sharifian, Maedeh, Ahlawat, Sushil
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AGA Institute. Published by Elsevier Inc. 2022
Materias:	AGA Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212618/ http://dx.doi.org/10.1016/S0016-5085(22)62385-0

Ejemplares similares

Tu1544: HUMORAL AND T CELL RESPONSES TO COVID-19 VACCINATION IN INFLAMMATORY BOWEL DISEASE
por: Zhang, Eva, et al.
Publicado: (2022)

Tu1550: REAL WORLD USE AND ADVERSE EVENTS OF SARS-COV-2 VACCINATION IN GREEK PATIENTS WITH INFLAMMATORY BOWEL DISEASE
por: Orfanoudaki, Eleni, et al.
Publicado: (2022)

Tu1552: PRESERVED SARS-COV-2 VACCINE CELL-MEDIATED IMMUNOGENICITY IN INFLAMMATORY BOWEL DISEASE PATIENTS ON IMMUNEMODULATING THERAPIES
por: Boland, Brigid S., et al.
Publicado: (2022)

Tu1549: IMPLEMENTATION AND SHORT-TERM ADVERSE EVENTS OF ANTI-SARSCOV-2 VACCINES IN INFLAMMATORY BOWEL DISEASE PATIENTS: AN INTERNATIONAL WEB-BASED SURVEY
por: Revés, Joana, et al.
Publicado: (2022)

Tu1546: JAPAN PROSPECTIVE MULTICENTER STUDY FOR OPTIMIZATION OF COVID-19 VACCINATIONS BASED ON THE IMMUNE RESPONSE AND SAFETY PROFILE IN INFLAMMATORY BOWEL DISEASE PATIENTS: INTERIM ANALYSES
por: Watanabe, Kenji, et al.
Publicado: (2022)

Tu1548: IMMUNE RESPONSE AFTER COVID-19 VACCINATION DURING MAINTANACE THERAPY IN IMMUNE-MEDIATED INFLAMMATORY DISEASES: AN OBSERVATIONAL COHORT STUDY
por: Dayam, R.M., et al.
Publicado: (2022)

Tu1551: PATIENTS WITH INFLAMMATORY BOWEL DISEASES HAVE IMPAIRED ANTIBODY PRODUCTION AFTER ANTI-SARS-COV-2 VACCINATION, ESPECIALLY THOSE ON ANTI-TNFα OR COMBINATION TREATMENT OF BIOLOGICS PLUS IMMUNOMODULATORS: RESULTS FROM A PANHELLENIC REGISTRY
por: Zacharopoulou, Eirini, et al.
Publicado: (2022)

Tu1554: A NOVEL METHOD FOR COLLECTING MICROBIOME SPECIMENS
por: Rahimian, Pejman, et al.
Publicado: (2022)

EP1270: SEROCONVERSION IN INFLAMMATORY BOWEL DISEASE PATIENTS AFTER COVID-19 VACCINATION
por: Horvath, Miklos, et al.
Publicado: (2022)

Su1495: COVID-19 VACCINE HESITANCY REMAINS HIGH IN INFLAMMATORY BOWEL DISEASE PATIENTS
por: Kwon, Hyuk Joon, et al.
Publicado: (2022)

Su1491: ATTITUDES AND PREDICTORS OF COVID-19 VACCINE UPTAKE IN INDIVIDUALS WITH INFLAMMATORY BOWEL DISEASE
por: Zhang, Eva, et al.
Publicado: (2022)

Su1498: SAFETY OF COVID-19 VACCINATION IN INFLAMMATORY BOWEL DISEASE PATIENTS ON BIOLOGIC THERAPY
por: Garrido, Isabel, et al.
Publicado: (2022)

656: POST-VACCINATION SYMPTOMS AFTER A THIRD DOSE OF SARS-COV-2 MRNA VACCINATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
por: Mujukian, Angela, et al.
Publicado: (2022)

Su1487: IMPACT OF INFLAMMATORY BOWEL DISEASE THERAPIES ON DURABILITY OF HUMORAL RESPONSE TO SARS COV-2 VACCINATION
por: Charilaou, Paris, et al.
Publicado: (2022)

Tu1110: EXPRESSION OF EPITHELIAL PROTEASES PREDICTS SARS-COV-2 ENTRY IN HUMAN ENTEROIDS
por: Alvarado, David M., et al.
Publicado: (2022)

Su1489: HUMORAL IMMUNOGENICITY OF THREE SARS-COV-2 MRNA VACCINE DOSES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
por: Schell, Trevor, et al.
Publicado: (2022)

Tu1041: EFFECT OF TIMING PROTOCOL ON AFTER-HOURS ENDOSCOPY FOR FOREIGN BODY INGESTIONS AND ESOPHAGEAL IMPACTIONS
por: Karb, Daniel B., et al.
Publicado: (2022)

Fr500 COVID-19 IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: SYSTEMATIC REVIEW AND META-ANALYSIS
por: Tripathi, Kartikeya, et al.
Publicado: (2021)

653: PATIENTS WITH INFLAMMATORY BOWEL DISEASE HAVE IMPAIRED HUMORAL BUT PRESERVED CELLULAR RESPONSES TO SARS-COV-2 MRNA VACCINATION
por: Li, Dalin, et al.
Publicado: (2022)

Su1484: SEROLOGICAL RESPONSES TO SARS-COV-2 VACCINATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A PROSPECTIVE COHORT STUDY
por: Quan, Joshua, et al.
Publicado: (2022)

654: A THIRD DOSE OF SARS-COV-2 VACCINE YIELDS HIGH ANTIBODY LEVELS COMPARED TO TWO DOSE VACCINATION SCHEDULE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
por: Quan, Joshua, et al.
Publicado: (2022)

Su1492: STRONG HUMORAL IMMUNE RESPONSE TO SARS-COV-2 VACCINE ADDITIONAL DOSE AMONG PATIENTS WITH INFLAMMATORY BOWEL DISEASES
por: Kappelman, Michael, et al.
Publicado: (2022)

Tu1033: IMPACT OF GERD ON PATIENTS UNDERGOING LUNG TRANSPLANTION FOR COVID-19: A SINGLE INSTITUTION RETROSPECTIVE STUDY
por: Kim, Christopher, et al.
Publicado: (2022)

Tu1108: INTERVAL CANCERS IN PATIENTS WITH HEREDITARY GASTROINTESTINAL SYNDROMES AFTER ONE YEAR OF THE SARS-COV-2 PANDEMIC
por: Barchi, Alberto, et al.
Publicado: (2022)

Su1611: POOR RESPONSE TO ANTI-SARS-COV-2 VACCINATION IN IMMUNOSUPPRESSED INFLAMMATORY BOWEL DISEASE PATIENTS IS ASSOCIATED WITH ALTERED GUT MICROBIOTA FUNCTION
por: Alexander, James L., et al.
Publicado: (2022)

Fr501 BIOLOGICS AND COVID-19 OUTCOMES IN INFLAMMATORY BOWEL DISEASE PATIENTS
por: Weissman, Simcha, et al.
Publicado: (2021)

Sa1056: RAPID IMPLEMENTATION OF AN EVIDENCE-BASED, VIRTUAL COVID-19 VACCINE EDUCATION CLINIC AT THE NOVA SCOTIA COLLABORATIVE INFLAMMATORY BOWEL DISEASE CLINIC (NSCIBD)
por: Komeylian, Hamed, et al.
Publicado: (2022)

Mo1018: THE T-CELL RESPONSE TO SARS-COV-2 VACCINATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IS OFTEN DEFICIENT IN ANTIBODY-RESPONDERS, AND AUGMENTED BY ANTI-TNF THERAPY
por: Li, Dalin, et al.
Publicado: (2022)

Tu1553: SPECIFIC IMMUNOGLOBLIN A INDUCED BY THE PERSISTENT COLONIZATION OF ADHERENT-INVASIVE E.COLI LIMITS PATHOBINT LOCALIZATION TO THE EPITHELIAL NICHE
por: Imai, Jin, et al.
Publicado: (2022)

Tu1040: COMPARATIVE EFFECTIVENESS OF VIRTUAL VS. IN-PERSON VISITS IN THE INITIAL EVALUATION OF ABDOMINAL PAIN PRIOR TO AND DURING THE COVID-19 PANDEMIC.
por: Sasankan, Priya, et al.
Publicado: (2022)

Fr497 INCIDENCE AND OUTCOMES OF COVID-19 IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE (IBD): A SYSTEMATIC REVIEW AND META-ANALYSIS
por: Khan, Shahab R., et al.
Publicado: (2021)

Fr496 THE EFFECTS OF COMORBIDITIES ON COVID-19 OUTCOMES AMONG PATIENTS WITH INFLAMMATORY BOWEL DISEASE
por: Parekh, Rajen, et al.
Publicado: (2021)

Fr502 INFLAMMATORY BOWEL DISEASE AND COVID-19: A LARGE INTEGRATED HEALTHCARE EXPERIENCE
por: Tashjian, Vartan C., et al.
Publicado: (2021)

Su1189 SAFETY OF IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH PREEXISTING INFLAMMATORY BOWEL DISEASE AND MICROSCOPIC COLITIS
por: Grover, Shilpa, et al.
Publicado: (2020)

Sa571 EVALUATION OF MENTAL STATE AND CLINICAL SYMPTOMS OF CORONAVIRUS PANDEMIC IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
por: Tani, Mizuki, et al.
Publicado: (2021)

Sa1064: IMPACT OF COVID-19 PANDEMIC ON PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A LOCAL REPORT
por: Tsipotis, Evangelos, et al.
Publicado: (2022)

Mo1055: COST-EFFECTIVENESS ANALYSIS OF SUBCUTANEOUS INFLIXIMAB FOR INFLAMMATORY BOWEL DISEASES IN SEQUENCIAL BIOLOGICAL TREATMENT
por: Baik, Deborah, et al.
Publicado: (2022)

Sa1053: OUTCOMES OF HOSPITALIZED COVID-19 PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A NATIONAL DATABASE STUDY
por: Melquist, Stephanie J., et al.
Publicado: (2022)

Tu1109: ENDOTHELIAL CELLS AND BLOOD VESSELS – CRITICAL TARGETS FOR COVID-19-INDUCED TISSUE INJURY AND SPREAD TO DISTANT ORGANS. UNDERLYING MECHANISMS INCLUDE ENDOTHELIAL DYSFUNCTION AND INJURY
por: Ahluwalia, Amrita, et al.
Publicado: (2022)

Su1488: WITHIN 6 MONTHS FROM COVID-19 BNT162B2 VACCINE PATIENTS WITH INFLAMMATORY BOWEL DISEASES TREATED WITH ANTI-TNFα HAVE SIGNIFICANTLY LOWER SEROLOGIC RESPONSES
por: Rabinowitz, Keren M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9an9khf4ctb4nug8s64g0gbhh8